Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Celcuity (Nasdaq: CELC) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on February 11-12, 2026. CEO and co‑founder Brian Sullivan will appear for a fireside chat at 9:30 a.m. ET on February 11, 2026. A live webcast and replay will be available via the company's Investors website.
Positive
- None.
Negative
- None.
News Market Reaction – CELC
On the day this news was published, CELC declined 3.07%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | NDA acceptance | Positive | -1.5% | FDA accepted NDA for gedatolisib with Priority Review and RTOR inclusion. |
| Dec 11 | Clinical data update | Positive | -1.0% | Updated Phase 3 VIKTORIA‑1 efficacy and safety data presented at SABCS. |
| Nov 26 | Conference presentation | Neutral | +0.8% | Announcement of accepted oral presentation for updated VIKTORIA‑1 data. |
| Nov 26 | Investor conference | Neutral | +1.3% | Participation in Evercore Healthcare Conference with CEO fireside chat. |
| Nov 17 | NDA submission | Positive | -0.5% | Completion of NDA submission to FDA for gedatolisib in advanced breast cancer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and regulatory milestones often coincided with modest negative price reactions, while neutral conference-related news saw small gains.
Over the last few months, Celcuity reported several key milestones for gedatolisib. On Nov 17, 2025, it completed its NDA submission, followed by updated Phase 3 VIKTORIA‑1 data and an SABCS presentation on Dec 11, 2025. The FDA then accepted the NDA with Priority Review on Jan 20, 2026. Separately, Celcuity has regularly participated in healthcare conferences, such as the Evercore event on Dec 2–4, 2025. Today’s Guggenheim summit appearance fits this pattern of ongoing investor and scientific visibility.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 to be held in New York, New York on February 11-12, 2026.
Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 9:30 a.m. ET on Wednesday, February 11, 2026. A live webcast of the event will be available using this weblink https://event.summitcast.com/view/kbtj9ZAiVkB78KPZiu5dZ9/2Q8oLmGM98qWAwr5LXWSr8. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, has completed enrollment and the company has reported detailed results for the PIK3CA wild-type cohort and has completed enrollment of patients for the PIK3CA mutant cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- ABC, is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924
